Literature DB >> 20589368

Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009.

S Lee1, P Glendenning, C A Inderjeeth.   

Abstract

The purposes of the study were to review available published literature on magnitude of non-adherence with osteoporosis regimens and to determine the association between frequency and modality of medication administration with patient preference and adherence. We searched peer-reviewed journal databases--MEDLINE, EMBASE, Biosis and Derwent Drug File for publications (January 1979 to January 2009) including MeSH terms--"patient preference", "adherence" and "compliance" based on "dosing frequency" and "modality". Since adherence was difficult to accurately quantify, preference, compliance and persistence were evaluated. Patients' preference and adherence at 12 months were higher with weekly over daily bisphosphonates (≥ 84% preference for weekly, medication possession ratios (MPR) 60-76% vs 46-64%; persistence 43.6-69.7% vs 31.7-55.7%). MPR reported for oral bisphosphonates were 68-71% at 12 months. At 2 years, only 43% of patients had MPR ≥ 80% for daily and weekly bisphosphonates. Observational studies (6-12 months) reported discontinuation rates of 18-22% for daily and 7% for weekly bisphosphonates. Data on monthly bisphosphonates are conflicting and confounded by cost differences, patient support programmes and definition of persistence. Studies suggest patient preference for annual zoledronic acid infusions over weekly bisphosphonates (66.4-78.8% vs 9.0-19.7%, respectively), but no data on compliance or persistence are available. Drug effectiveness, side effects and route of administration were more important than frequency. Although less frequent dosing is preferred, other factors such as perceived efficacy, side effects, medication cost, availability of patient support programmes and route of delivery are equally important. Adherence is complex and difficult to quantify and may not be exclusively influenced by frequency of medication administration.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20589368     DOI: 10.1007/s00198-010-1335-x

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  53 in total

1.  Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial.

Authors:  A M Grant; A Avenell; M K Campbell; A M McDonald; G S MacLennan; G C McPherson; F H Anderson; C Cooper; R M Francis; C Donaldson; W J Gillespie; C M Robinson; D J Torgerson; W A Wallace
Journal:  Lancet       Date:  2005 May 7-13       Impact factor: 79.321

2.  An evaluation of patient preferences for osteoporosis medication attributes: results from the PREFER-US study.

Authors:  Thomas W Weiss; Deborah T Gold; Stuart L Silverman; Colleen A McHorney
Journal:  Curr Med Res Opin       Date:  2006-05       Impact factor: 2.580

3.  Medication persistence with weekly versus daily doses of orally administered bisphosphonates.

Authors:  Mark P Ettinger; Rich Gallagher; Paul E MacCosbe
Journal:  Endocr Pract       Date:  2006 Sep-Oct       Impact factor: 3.443

4.  Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.

Authors:  B Ettinger; D M Black; B H Mitlak; R K Knickerbocker; T Nickelsen; H K Genant; C Christiansen; P D Delmas; J R Zanchetta; J Stakkestad; C C Glüer; K Krueger; F J Cohen; S Eckert; K E Ensrud; L V Avioli; P Lips; S R Cummings
Journal:  JAMA       Date:  1999-08-18       Impact factor: 56.272

5.  Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Authors:  Dennis M Black; Pierre D Delmas; Richard Eastell; Ian R Reid; Steven Boonen; Jane A Cauley; Felicia Cosman; Péter Lakatos; Ping Chung Leung; Zulema Man; Carlos Mautalen; Peter Mesenbrink; Huilin Hu; John Caminis; Karen Tong; Theresa Rosario-Jansen; Joel Krasnow; Trisha F Hue; Deborah Sellmeyer; Erik Fink Eriksen; Steven R Cummings
Journal:  N Engl J Med       Date:  2007-05-03       Impact factor: 91.245

6.  Compliance with pharmacologic therapy for osteoporosis.

Authors:  Robert A Yood; Srinivas Emani; John I Reed; Barbara Edelman Lewis; Mary Charpentier; Eva Lydick
Journal:  Osteoporos Int       Date:  2003-09-19       Impact factor: 4.507

7.  Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: A randomized, crossover study (BALTO II).

Authors:  Peyman Hadji; Helmut Minne; Michael Pfeifer; Pierre Bourgeois; Patrice Fardellone; Angelo Licata; Vipul Devas; Daiva Masanauskaite; Elizabeth Barrett-Connor
Journal:  Joint Bone Spine       Date:  2007-10-22       Impact factor: 4.929

8.  Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass.

Authors:  D L Kendler; L Bessette; C D Hill; D T Gold; R Horne; S F Varon; J Borenstein; H Wang; H-S Man; R B Wagman; S Siddhanti; D Macarios; H G Bone
Journal:  Osteoporos Int       Date:  2009-08-06       Impact factor: 4.507

9.  Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study.

Authors:  James A Simon; E Michael Lewiecki; Mary E Smith; Richard A Petruschke; Lixia Wang; Joanne J Palmisano
Journal:  Clin Ther       Date:  2002-11       Impact factor: 3.393

10.  Osteoporosis medication profile preference: results from the PREFER-US study.

Authors:  Thomas W Weiss; Colleen A McHorney
Journal:  Health Expect       Date:  2007-09       Impact factor: 3.377

View more
  20 in total

Review 1.  Ibandronate: A Review in Japanese Patients with Osteoporosis.

Authors:  Gillian M Keating
Journal:  Drugs Aging       Date:  2016-04       Impact factor: 3.923

2.  Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards: osteoporos int 2011;22:391-420.

Authors:  Paul Glendenning
Journal:  Clin Biochem Rev       Date:  2011-02

3.  Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate.

Authors:  J P Brown; C Roux; P R Ho; M A Bolognese; J Hall; H G Bone; S Bonnick; J P van den Bergh; I Ferreira; P Dakin; R B Wagman; C Recknor
Journal:  Osteoporos Int       Date:  2014-03-28       Impact factor: 4.507

Review 4.  Osteoporosis: a discussion on the past 5 years.

Authors:  Kyle M Schweser; Brett D Crist
Journal:  Curr Rev Musculoskelet Med       Date:  2017-06

5.  Improving adherence to and persistence with oral therapy of osteoporosis.

Authors:  M L Bianchi; P Duca; S Vai; G Guglielmi; R Viti; C Battista; A Scillitani; S Muscarella; G Luisetto; V Camozzi; R Nuti; C Caffarelli; S Gonnelli; C Albanese; V De Tullio; G Isaia; P D'Amelio; F Broggi; M Croci
Journal:  Osteoporos Int       Date:  2015-01-27       Impact factor: 4.507

6.  Patient weighting of osteoporosis medication attributes across racial and ethnic groups: a study of osteoporosis medication preferences using conjoint analysis.

Authors:  S Silverman; A Calderon; K Kaw; T B Childers; B A Stafford; W Brynildsen; A Focil; M Koenig; D T Gold
Journal:  Osteoporos Int       Date:  2012-12-18       Impact factor: 4.507

7.  Osteoporosis medication adherence: physician perceptions vs. patients' utilization.

Authors:  Jeffrey R Curtis; Qian Cai; Sally W Wade; Bradley S Stolshek; John L Adams; Akhila Balasubramanian; Hema N Viswanathan; Joel D Kallich
Journal:  Bone       Date:  2013-03-15       Impact factor: 4.398

8.  Long-term persistence and switching patterns among women using osteoporosis therapies: 24- and 36-month results from POSSIBLE US™.

Authors:  S W Wade; S Satram-Hoang; B S Stolshek
Journal:  Osteoporos Int       Date:  2014-06-19       Impact factor: 4.507

Review 9.  Adherence and preference of intravenous zoledronic acid for osteoporosis versus other bisphosphonates.

Authors:  Maria José Fobelo Lozano; Susana Sánchez-Fidalgo
Journal:  Eur J Hosp Pharm       Date:  2017-09-20

10.  Seasonal Variation and Global Public Interest in the Internet Searches for Osteoporosis.

Authors:  Chao Wang; Xiong Shu; Jianfeng Tao; Yanzhuo Zhang; Yue Yuan; Chengai Wu
Journal:  Biomed Res Int       Date:  2021-06-04       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.